ReviewJournal of hematology & oncology2021

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.

Kai Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.